Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?
Abstract Background Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carci...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08315-4 |
id |
doaj-4c74b931df3b464383fd21e7f671e570 |
---|---|
record_format |
Article |
spelling |
doaj-4c74b931df3b464383fd21e7f671e5702021-05-23T11:46:40ZengBMCBMC Cancer1471-24072021-05-012111510.1186/s12885-021-08315-4Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients?Aman Chauhan0Satya Das1Rachel Miller2Laura Luque3Samuel N. Cheuvront4James Cloud5Zach Tarter6Fariha Siddiqui7Robert A. Ramirez8Lowell Anthony9Division of Medical Oncology, University of KentuckyDivision of Medical Oncology, Vanderbilt University Medical CenterMarkey Cancer Center, University of KentuckyScience & Technology, Entrinsic Bioscience Inc.Science & Technology, Entrinsic Bioscience Inc.School of Medicine, University of KentuckySchool of Medicine, University of KentuckySchool of Medicine, University of KentuckyDivision of Oncology Ochsner Health SystemDivision of Medical Oncology, University of KentuckyAbstract Background Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. Methods A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. Results Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3–20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0–11). Conclusions Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients.https://doi.org/10.1186/s12885-021-08315-4Neuroendocrine tumorsAmino acid oral rehydration solutionDiarrheaExcess bowel movements |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aman Chauhan Satya Das Rachel Miller Laura Luque Samuel N. Cheuvront James Cloud Zach Tarter Fariha Siddiqui Robert A. Ramirez Lowell Anthony |
spellingShingle |
Aman Chauhan Satya Das Rachel Miller Laura Luque Samuel N. Cheuvront James Cloud Zach Tarter Fariha Siddiqui Robert A. Ramirez Lowell Anthony Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? BMC Cancer Neuroendocrine tumors Amino acid oral rehydration solution Diarrhea Excess bowel movements |
author_facet |
Aman Chauhan Satya Das Rachel Miller Laura Luque Samuel N. Cheuvront James Cloud Zach Tarter Fariha Siddiqui Robert A. Ramirez Lowell Anthony |
author_sort |
Aman Chauhan |
title |
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
title_short |
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
title_full |
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
title_fullStr |
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
title_full_unstemmed |
Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
title_sort |
can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-05-01 |
description |
Abstract Background Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. Methods A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. Results Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3–20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0–11). Conclusions Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients. |
topic |
Neuroendocrine tumors Amino acid oral rehydration solution Diarrhea Excess bowel movements |
url |
https://doi.org/10.1186/s12885-021-08315-4 |
work_keys_str_mv |
AT amanchauhan cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT satyadas cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT rachelmiller cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT lauraluque cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT samuelncheuvront cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT jamescloud cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT zachtarter cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT farihasiddiqui cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT robertaramirez cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients AT lowellanthony cananaminoacidmixturealleviategastrointestinalsymptomsinneuroendocrinetumorpatients |
_version_ |
1721429324906627072 |